Topic

Politics

11
Dec
2017

Biotech’s Test: Root for a Tax Windfall Or Support the Next Generation of Scientists?

Grad students are underpaid and underappreciated. Many barely scrape by. Stagnant grant funding for science and uncertain career prospects are the norm. Yet we all know grad students are the mitochrondria of the scientific enterprise. Without them, PIs wouldn’t be looking like geniuses in Nature and Science. Biotech companies wouldn’t have enough of the worker bees they need. Now we...
Read More
17
Aug
2017

We Can Follow Through On Our Own After Charlottesville

[Editor’s Note: Steve Graham of Fenwick & West is one of biotech’s leading corporate attorneys. His book, “Invisible Ink: Navigating racism in corporate America” was published in April.] I spent my first few years of elementary school in segregated schools.  Beaches were segregated.  The drinking fountains and restrooms were labeled.  At movie theatres, colored people were directed to the balcony.  At...
Read More
16
Aug
2017

At What Price a Seat at the Table?

[Editor’s Note: This editorial was co-authored by Steve Holtzman, CEO of Decibel Therapeutics, and Jeremy Levin, CEO of Ovid Therapeutics in the aftermath of violent clashes between white supremacists and counter-protesters in Charlottesville, Virginia.] FACT 1: The overwhelming majority of the men and women in the biopharmaceutical industry, scientists and non-scientists alike, have been drawn to their profession by the noble...
Read More